Find the answers you need about sacral neuromodulation therapy from Medtronic with devices that can help you experience life-changing relief.
If you’re suffering from bladder or bowel problems, you’re not alone. In fact, studies show one in six adults suffers from overactive bladder (OAB),1 and one in twelve have reported symptoms of fecal incontinence (FI).2,3
You’re taking the right steps to get the relief you seek, but it’s only natural to want to know more before getting started. You can find more information to help you make a decision.
A: Medtronic bladder and bowel control therapy delivered by the InterStim™ system restores* bladder or bowel function by gently stimulating the sacral nerves.5-7
A: Research suggests that bladder and bowel control problems may be caused by miscommunication between the brain and the sacral nerves that are responsible for controlling bladder and bowel function.5-7
A: With this therapy, you may experience improved symptom relief allowing for fewer trips to the bathroom, fewer accidents, more confidence and more freedom.8-10
A: In addition to risks related to surgery, complications can include pain at the implant site, new pain, infection, lead (thin wire) movement/migration, device problems, undesirable changes in urinary or bowel function, and uncomfortable stimulation (sometimes described as a jolting or shocking feeling). Talk to your doctor about ways to minimize these risks.
A: Overactive bladder and fecal incontinence are chronic conditions. InterStim™ therapy helps manage the symptoms but does not cure these conditions.
A: The life of a device is impacted by many things, including device settings, placement, and other factors. Under expected therapy settings the InterStim™ Micro device can last up to 15 years and the InterStim X™ device can last over 10 years.†
A: Most people describe it as a slight pulling, tingling, or fluttering sensation in the pelvic area. The stimulation is always adjustable and should not be painful.
A: You can try it before you decide, and it's reversible if you change your mind later. For bladder and bowel control, the InterStim™ systems deliver sacral neuromodulation (SNM) therapy that has been shown to be more effective than medications for overactive bladder (OAB).‡,11 And unlike injections, this therapy doesn’t require self-catheterization or repeated treatment visits.12
A: You can have a full-body§ MRI scan if certain conditions are met. Your clinician can provide more details about these conditions, as well as safety information.
A: Since its approval in 1997 for overactive bladder and 2011 for fecal incontinence, the InterStim™ system has been used to treat these problems in more than 375,000 patients worldwide.
A: Medicare and many private insurance companies cover this therapy. Talk to your doctor and your insurance provider to learn more about your coverage.
Prospective patients, reach an education specialist: (800) 664-5111
Existing patients, reach a service specialist: (800) 510-6735
Have more questions?
Don’t hesitate to reach out.
Patient services specialist:
Medtronic Ambassadors are people who have volunteered to talk to prospective patients about their personal experience with a specific Medtronic therapy.
The Medtronic Ambassador Program is not intended to offer medical advice or to replace a conversation with a physician. For medical or technical questions, contact your licensed physician or healthcare professional.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.
Restoration of function is defined as a 50 percent or greater reduction in your troublesome bladder or bowel symptoms from baseline.
Under expected therapy settings and telemetry use
Under certain conditions; see approved labeling for details. Patients with InterStim™ SureScan™ MRI leads only.
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336.
Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterol. 2009;137(2):512–517.
Ditah I, Devaki P, Luma HN et al. Prevalence, trends, and risk factors for fecal incontinence in United States adults, 2005-2010. Clin Gastroenterol Hepatol. 2014;12:636–643.
Griﬃths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862–1867.
Patton V, Wiklendt L, Arkwright JW, et al. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013;100(7):959–968.
Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491–501.
Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromod. 2000;3(1):15–26.
Siegel S, Noblett K, Mangel J, et al. Five-year follow-up results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol. 2018;199(1), 229–236.
Medtronic InterStim™ therapy clinical summary (2018).
Hull T, Giese C, Wexner SD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013; 56(2):234–245.
Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim™ therapy compared to standard medical therapy at six months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230.
Yeaw J, Benner J, Walt JG et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009:15(9):724–736.